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Abstract
Atherosclerosis is a chronic, progressive, inflammatory disease affecting many vascular beds.
Disease progression leads to acute cardiovascular events such as myocardial infarction, stroke and
death. The diseased carotid alone is responsible for one third of the 700,000 new or recurrent
strokes occurring yearly in the United States. Imaging plays an important role in the management
of atherosclerosis, and cardiovascular magnetic resonance (CMR) of the carotid vessel wall is one
promising modality in the evaluation of patients with carotid atherosclerotic disease. Advances in
carotid vessel wall CMR allow comprehensive assessment of morphology inside the wall,
contributing substantial disease-specific information beyond luminal stenosis. Although carotid
vessel wall CMR has not been widely used to screen for carotid atherosclerotic disease, many trials
support its potential for this indication. This review summarizes the current state of knowledge
regarding carotid vessel wall CMR and its potential clinical application for management of carotid
atherosclerotic disease.
Introduction
The common carotid artery bifurcation is a zone of fre-
quent atherosclerotic disease owing to the disturbed
hemodynamics in the carotid bulb. Estimates place
carotid atherosclerosis as the embolic source behind up to
30% of the 700,000 new or recurrent strokes annually in
the United States [1]. With 5.8 million stroke survivors in
the U.S., stroke is the leading cause of long-term disability
and results in direct and indirect costs of $68.9 billion per
year [2]. As a common source of stroke, carotid atheroscle-
rosis contributes substantially to the overall healthcare
burden and costs both in the U.S. and worldwide.
To assess the risk of stroke from carotid atherosclerotic
disease, the current standard is to measure the severity of
luminal stenosis by angiography. Both the European
Carotid Surgery Trial (ECST) and the North American
Symptomatic Carotid Endarterectomy Trial (NASCET)
showed that individuals with prior ischemic symptoms
and carotid stenosis in excess of 50% were at very high risk
of stroke and that the risk was significantly reduced by sur-
gery [3,4]. In asymptomatic individuals, studies are more
equivocal and the benefit of surgery or screening for
asymptomatic stenosis is hotly debated [5-8]. Notably,
asymptomatic carotid stenosis in excess of 50% is very
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common with prevalence estimated at 12.5% in men and
6.9% in women over age 70 [9].
Furthermore, patients with high-grade stenosis likely rep-
resent just a fraction of those at risk of stoke due to carotid
atherosclerosis. Given the unique geometry of the carotid
bulb, which generally is larger in diameter than the more
distal internal carotid, it is possible to have a minimal ste-
nosis despite the presence of significant plaque burden.
Furthermore, luminal stenosis measurement may under-
estimate plaque burden because of compensatory, expan-
sive arterial remodeling, as originally described by Glagov
[10]. Consequently, large advanced plaques are com-
monly observed in carotid arteries without measurable
stenosis [11] and have been implicated in thromboem-
bolic complications [12].
Given the uncertainty in patient management for high-
grade asymptomatic stensosis and the failure of stenosis
to characterize risk from lesions that do not compromise
the lumen, better strategies for risk assessment are needed.
Cardiovascular magnetic resonance (CMR) of the carotid
vessel wall provides a new imaging approach with poten-
tial to identify the characteristics of the carotid atheroscle-
rotic lesion itself. Carotid vessel wall CMR uses a
combination of bright-blood and black-blood techniques
to provide information regarding the structure of the
carotid artery and the composition of the atherosclerotic
plaque. These structural and compositional features are
thought to play the central role in determining the risk
posed by a carotid lesion. Thus, carotid vessel wall CMR
may be the much needed tool for determining risk above
and beyond stenosis.
The potential for direct and indirect clinical impact of
carotid vessel wall CMR is not, however, limited to near-
term stroke prediction. The ideal therapeutic approach
would prevent the high-risk lesion from ever developing.
In this regard, carotid CMR has the potential to evaluate
the performance of therapies in clinical trials, and to iden-
tify new targets for therapy to prevent progression toward
high-risk lesions. Carotid CMR may also play a role in
selecting and monitoring optimal therapy for specific
lesion characteristics. Finally, the carotid artery can be
used as a systemic marker of overall cardiovascular health
to be assessed by carotid CMR.
To understand the many roles that carotid CMR can play
in clinical management of carotid atherosclerosis, this
review describes the near-term feasibility and capability of
carotid vessel wall CMR. By considering how carotid
atherosclerotic tissues appear on CMR, image interpreta-
tion criteria are provided for the key targets. We examine
the carotid atherosclerotic plaque in various stages from
the already disrupted plaque back to the early stage of
plaque formation to see how CMR can play a role in each
stage. The direct and potential clinical impacts of carotid
vessel wall CMR are addressed.
Feasibility of Clinical Carotid vessel wall CMR
The attractiveness of CMR for assessment of the carotid
artery wall derives from several factors. From a general
imaging perspective, the carotid artery has beneficial
physiology given its relatively large size, superficial loca-
tion and remoteness from heart and lung motion. Phased-
array surface coils designed for carotid artery provide suf-
ficient signal-to-noise ratio (SNR) for the high-resolution
imaging required for characterizing plaque composition
[13,14]. CMR itself comes with the standard benefits of
being non-invasive and avoiding the use of ionizing radi-
ation, which is particularly important for serial imaging
studies.
The foremost advantage of CMR for this application is the
ability to combine information from multiple contrast
weightings. Through early investigations, a standardized
carotid vessel wall CMR protocol emerged consisting of
black-blood fast spin echo sequences including T1-
weighted (T1W), T2-weighted (T2W), and proton density
weighted (PDW) imaging with fat suppression, combined
with a bright-blood time of flight (TOF) sequence [15].
More recently, highly T1-weighted gradient echo
sequences such as Magnetization-Prepared Rapid Acquisi-
tion Gradient-Echo (MP-RAGE) have been incorporated
into carotid protocols [16]. Furthermore, these techniques
can be augmented with injected contrast agents that pro-
vide improved or complementary information regarding
plaque composition [17-19].
The availability of carotid plaque specimens from carotid
endarterectomy has enabled the contrast features of
plaque components to be validated and described in
detail [20]. These studies have utilized serial histological
cross sections with specialized staining to compare with
the contrast features in corresponding cross-sectional
CMR images acquired in vivo. Characteristics of common
plaque components on CMR are summarized in Table 1.
The optimal combination of contrast weightings depends
on the imaging target(s) and will be discussed at length in
the subsequent sections of this review.
Technical considerations
Perhaps the greatest challenge for carotid wall CMR is the
resolution to distinguish the internal plaque structure.
Even in advanced disease, the vessel wall may only meas-
ure a few millimeters in thickness, with the potential exist-
ence of multiple substructures across that dimension.
These structures also change shape rapidly in the longitu-
dinal direction of the artery. Thus, 2D imaging
approaches have had to contend with in-plane resolutionsJournal of Cardiovascular Magnetic Resonance 2009, 11:53 http://www.jcmr-online.com/content/11/1/53
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of 0.6 mm or less and slice thickness of 2-3 mm. Recently,
3D isotropic imaging approaches have been proposed
with isotropic resolution up to 0.6 mm [21]. In both 2D
and 3D approaches, this resolution pushes the SNR limits
of the scanner, requiring long acquisition times. Minimiz-
ing patient motion during the scan with the use of com-
fortable head holders or motion-corrected scanning is
critical. Also, because of SNR limitations, the use of paral-
lel imaging to reduce scan time is not recommended.
The increasing availability of 3.0 Tesla field-strength scan-
ners provides some SNR benefits for carotid vessel wall
CMR. Compared to 1.5 T CMR, black-blood carotid artery
MR images at 3.0 Tesla have been found to have 1.4-2.4
times increased carotid wall SNR and lumen/wall con-
trast-to-noise ratio [22-24]. The higher SNR can be traded
for reduced scan time of up to about 40-50% [22].
The novel developments of coils, sequences, and scanner,
taken together, are a driving force for carotid vessel wall
CMR to obtain higher spatial resolution within a reasona-
ble scanning time on a clinically available scanner.
Image postprocessing
The importance of quantification in evaluating plaque
burden and composition suggests a role for image post-
processing techniques. Highly automated measurement
techniques can reduce analysis time, reduce reader-
dependent bias, and improve measurement reproducibil-
ity. Several semi-automated imaging processing tools
have been used to quantitative indices of plaque burden
and composition [25-27]. Underhill et al. proposed a
technique using active shape models to segment the vessel
boundaries [28]. Utilizing morphologic information such
as local wall thickness, Liu et al. proposed a flexible,
multi-contrast plaque segmentation technique (Morphol-
ogy-Enhanced Probabilistic Plaque Segmentation,
MEPPS) that is suitable for measuring plaque composi-
tion in vivo [27]. Recently, Kerwin et al. described a plaque
analysis software (The Computer-Aided System for Cardi-
ovascular Disease Evaluation, CASCADE) to provide
quantitative information regarding plaque burden and
composition, which was highly similar to manual outlin-
ing but with considerably less analysis time [29].
CMR appearance of Carotid Plaque
Disrupted plaque
For CMR, the most important clinical question to be
answered for patients with established carotid lesions is
whether the lesion poses a high, near-term risk for compli-
cations. Retrospective histological studies of carotid
atherosclerotic lesions implicated in ischemic stroke and
transient ischemic attacks have found those lesions to
exhibit plaque disruption, most commonly fibrous cap
rupture (Figure 1). Spagnoli et al. reported ipsilateral
fibrous cap rupture was observed in 66.7% (64/96) of
patients with major stroke, 23.1% (21/91) of patients
with transient ischemic attack, and only 13.4% (11/82) of
patients without prior ischemic symptoms [30]. Similarly,
Carr et al. found that cap rupture occurred more fre-
quently in symptomatic patients (74%) than in asympto-
matic patients (32%) [31]. Once an atherosclerotic plaque
is disrupted, the thrombogenic contents and lipid core are
exposed to platelets and coagulation factors in circulating
blood, predisposing the patient to an acute thromboem-
bolic event. The study by Spagnoli et al. found that an
acute thrombus was associated with cap rupture in 90.1%
(64/71) patients with stroke. The clinical significance of
plaque disruption begs the question whether CMR can
visualize cap rupture. Of note, fibrous cap rupture and
thrombosis can also occur in the carotid artery without
overt clinical symptoms. Prior sites of rupture and throm-
bus can act as further stimuli for thrombus development.
Thus, identification of these features on carotid vessel wall
CMR could be an important part of a risk reduction strat-
egy of stroke.
To visualize plaque disruption and thrombus, black-
blood CMR sequences (T1W, T2W or PD) permit a clear
differentiation of both the lumen and outer wall bounda-
ries by suppressing the signal from flowing blood. Plaque
disruption can be identified by an ulceration of the plaque
surface, the discontinuity of fibrous cap, and thrombus on
the surface (Figure 2). In a histology-validated study of 26
patients scheduled for endarterectomy, Kampschulte et al.
was able to detect luminal and juxtaluminal thrombus
with an accuracy of 96%, by using an in vivo multi-con-
trast approach that primarily identified hyper-intense sig-
nals on TOF and T1W images that appeared to have direct
contact with the lumen [32]. Moody et al. also used a non
Table 1: Carotid CMR Characteristics
TOF T1W T2W PD CE-T1W*
Fibrous tissue oo o o o
Calcification -- - - -
Lipid-Rich Necrotic Core oo - - / o -
Hemorrhage ++- / + - / + -
Note: + indicates hyper-intense; o indicates iso-intense; - indicates hypo-intense
*Contrast enhanced T1W (CE-T1W): + indicates enhancement present; - indicates enhancement absentJournal of Cardiovascular Magnetic Resonance 2009, 11:53 http://www.jcmr-online.com/content/11/1/53
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contrast-enhanced CMR method based on the T1-shorten-
ing properties of methemoglobin combined with a highly
T1-weighted gradient echo protocol ("direct thrombus
imaging") to identify hyper-intense regions of thrombus
in the carotid artery [33].
In addition, black-blood sequences combined with
bright-blood imaging techniques (3-dimensional TOF)
can distinguish intact thick cap from intact thin and dis-
rupted cap based on the lumen surface condition and the
presence of a dark band along the lumen surface in TOF
images [34]. The addition of gadolinium contrast agents,
which lead to increase fibrous cap signal on T1W images,
further aids in reliable assessment of fibrous cap status. A
multi-contrast weighted CMR study including contrast
enhanced images by kwee et al., found good intra- and
inter-reader agreement (k = 0.96 for intra-reader; k = 0.64
for inter-reader) for fibrous cap status [35].
Thin Fibrous Cap and Lipid-Rich Necrotic Core (LRNC)
While detection of prior plaque rupture has clinical impli-
cations, a more compelling question is whether detectable
precursors of cap rupture exist. The concept of the disrup-
tion-prone or high-risk/vulnerable plaque, initially
derived from coronary studies, has been increasingly
shown to apply in the carotid circulation. Histological
studies have shown that the most common feature of
plaques prone to rupture is a thin fibrous cap with a large
underlying necrotic core (Figure 3) [36-39]. These features
are key targets of carotid vessel wall CMR and are potential
imaging markers for risk of stroke/transient ischemic
attack.
The well established results in the visualization of lipid-
rich necrotic core (LRNC) have come from the use of
black blood multi-contrast images (T1W, PDW, and T2W)
using criteria that compares the signal intensity of the
adjacent sternocleidomastoid muscle to the signal intensi-
ties of the black blood sequences [40-42]. The LRNC is a
mixture of lipid, cellular debris, blood and water in vari-
ous concentrations therefore MR signal intensities of the
different sequences reflect those variations. In general, the
LRNC appears isointense on T1W and TOF images, and
hypointense on T2W images. An ex vivo carotid CMR study
by Fabiano et al. using these criteria found the sensitivity
and specificity for identifying the lipid core according to
these criteria were 92% and 74% respectively [43]. A
quatitative in vivo study by Saam et al. produced a 92% of
sensitivity and 65% for specificity comparing the size of
the lipid rich necrotic core to corresponding histology
[44].
Gadolinium-based contrast agents provided additional
information for characterization of the necrotic core and
the fibrous cap (Figure 4) [17,18,45]. The addition of con-
trast agent can increase the signal intensity of fibrous tis-
sue by 79.5% due to the presence of microvasculature;
conversely, due to the lack of microvasculature, the
necrotic core has the least enhancement 28.6% [17]. The
minimal enhancement of the LRNC results in good con-
trast with fibrous tissue and can be used to determine the
boundary of the necrotic core with good accuracy as
shown in Figure 4. Wasserman et al. found that gadolin-
ium-enhanced T1W images could delineate the fibrous
cap from the LRNC, with a contrast-to-noise ratio similar
or better than that of T2W images but with approximately
twice the signal-noise-ratio [18]. Takaya et al. also found
that in vivo CMR measurement of LRNC size was more
reproducible when using contrast agent [46]. Cai et al.
took contrast one-step further by comparing the size of
the enhanced fibrous cap to corresponding histology (For
maximal thickness: r = 0.78, p < 0.001; for length: r = 0.73,
p < 0.001; for area: r = 0.73, p < 0.001) [45].
Intraplaque hemorrhage
Intraplaque hemorrhage is thought to originate primarily
from immature neovessels within the plaque that are
prone to leakage [47]. The role of intraplaque hemorrhage
in plaque development and rupture is not fully under-
stood, but is currently believed to be a driving force in
plaque progression through lipid accumulation from red
blood cells [48]. It has also been implicated as a risk factor
for plaque disruption, although previous studies testing
its association with symptoms have varied results
[32,49,50].
The Ruptured Carotid Plaque Figure 1
The Ruptured Carotid Plaque. A Movat's Pentachrome 
stain of a common carotid fibrous cap disruption. The disrup-
tion (big arrow) is framed by two branches of the fibrous cap 
(asterisks) on the right side, and a cap overlaid with throm-
bus on the left (small arrow). The chevron points to a region 
of organizing thrombus. (Magnification 100×, inset 10×)
* *Journal of Cardiovascular Magnetic Resonance 2009, 11:53 http://www.jcmr-online.com/content/11/1/53
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Intraplaque hemorrhage (Figure 5) is most reliably
detected by CMR in the methemoglobin stage due to short
T1 relaxation time leading to hyper-intense signal on T1W
images. In 2004 Chu et al. used a combined black blood
T1 weighted turbo spin echo (TSE) sequence and a time of
flight (TOF) sequence for hemorrhage detection. Hemor-
rhage was identified by hyper-intense signal intensity on
both the TOF and T1W images. A T2W black blood TSE
sequence was used to stage the early (hypo-intense on
T2W images) or later phase (iso- or hyper-intense o) of the
methemoglobin phase. Validation with corresponding
histology showed that the technique had a sensitivity of
0.85 - 0.95 and specificity of 0.7 - 0.77 [51]. Moody et al.
proposed another approach to the identification of intra-
plaque hemorrhage by using a heavily T1 weighted
sequence 3D MP-RAGE (Magnetization-Prepared Rapid
Acquisition Gradient-Echo) [16,52]. This technique takes
advantage of the short T1 relaxation time of methemo-
globin and produces a very bright signal. The technique
has a reported sensitivity and specificity of 84% and 84%
[52]. The limitation of MP-RAGE is that by using only the
T1 shortening effect of methemoglobin, it cannot be used
to differentiate the various stages of intraplaque hemor-
rhage.
Calcification
Calcification is commonly found in atherosclerosis and
occurs both in areas that are viable and necrotic. Since the
role of calcium deposition and its contribution to plaque
stability is not well understood, there is a debate as to the
extent to which plaque calcification contributes to plaque
stability. Some studies demonstrated that the presence
and extent of calcification may be associated with
increased risk of plaque rupture [53-57], whereas others
suggested that it has beneficial effects in stabilizing the
plaque, making it stiffer and less prone to rupture [58-60].
There is current growing interest in the location of cal-
cium, which may affect plaque vulnerability. Using a bio-
mechanical model, Li et al. showed that predicted
maximum stress was increased by 47.5% when calcium
deposits were located in the thin fibrous cap. While the
presence of calcium deposits in the lipid core or remote
from the fibrous cap resulted in no increase in maximum
stress [61,62]. It was conjectured that the presence of cal-
cification within the lipid core may even stabilize the
plaque by adding bulk [61]
MR imaging is able to detect plaque calcification with
good sensitivity and specificity. Calcification (Figure 6)
produces a hypo-intense signal on all contrast weightings
due to low water content [63,64]. An 1.5 T CMR investiga-
tion by Fabiano et al. demonstrated that CMR has high
sensitivity (98%) and specificity (99%) for the identifying
plaque calcification [43]. Furthermore, Saam et al.
reported a strong correlation between CMR and corre-
sponding histology calcification area measurements (r =
0.74,  p  < 0.001) [44]. At higher field strengths, the
increased susceptibility of calcification may alter quantifi-
cation and/or detection. Underhill et al. compared the
quantification of carotid calcification at 1.5 T with those
at 3.0 T magnetic resonance imaging, and found that the
measurement of calcification was significantly larger at
Magnetic Resonance Images of the Ruptured Carotid Plaque Figure 2
Magnetic Resonance Images of the Ruptured Carotid Plaque. The bright-blood 3D TOF image shows a distinct dis-
ruption of the fibrous cap (block arrow), corresponding to the hypointense juxtaluminal region on T1W and CE-T1W images. 
The hyperintense signal present in the necrotic core adjacent to the rupture (arrow) indicates presence of intraplaque hemor-
rhage inside of a lipid-rich necrotic core (thin arrow on CE-T1W image). Asterisks are placed on the sternocleidomastoid mus-
cle, which is used to determine plaque signal intensities. The scan was acquired on a 3.0-T GE Signa Excite along with the use 
of a 4-element phased-array carotid coil.Journal of Cardiovascular Magnetic Resonance 2009, 11:53 http://www.jcmr-online.com/content/11/1/53
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3.0 T (mean area of 7.9 mm2 vs. 5.9 mm2, p = 0.03), but a
high intraclass correlation of 0.79 was maintained [64].
Inflammation
Inflammation is the process by which the body responds
to injury. In atherosclerotic disease the injury is the accu-
mulation of lipids in the artery wall. As the lesion evolves
proinflammaotry cytokines are expressed. These cytokines
initiate a cascade that trigger endothelial cells to express
adhesion molecules which then allow for the attachment
of blood leucocytes [65]. The infiltration of inflammatory
cells into the wall is the hallmark of early atherosclerotic
disease and has been implicated in plaque rupture of
advanced disease [66]. In the progression of carotid
atherosclerosis, inflammation is characterized by
increased endothelial permeability, macrophage infiltra-
tion, hypoxia within the vessel wall, and growth of the
adventitial vasa vasorum. The recruited macrophages con-
sume lipids, undergo apoptosis and thereby contribute to
the development and growth of the necrotic core [66].
Within the atherosclerotic plaque, the distribution of
inflammation is also associated with plaque stability (Fig-
ure 7). Inflammation is prevalent on the edges of the
necrotic core and most importantly in the fibrous cap cov-
ering the core [67-71]. As inflammation progresses micro-
vessels are recruited to supply the burgeoning population
of cells. Moreno et al. found that microvessel density not
only increased with inflammation but also correlated with
plaque rupture [72]. Mofidi et al. found a significant asso-
ciation of increased microvasculature and with intra-
plaque hemorrhage, unstable atherosclerotic lesions and
lesions obtained from symptomatic patients [73].
Based on the importance of plaque inflammation in
determining the risk of progression or rupture considera-
ble interest exists in the detection of vessel wall inflamma-
tion and its precursors. One CMR technique for assessing
inflammatory burden in atherosclerosis is dynamic con-
trast enhanced CMR (DCE-CMR) with kinetic analysis of
the contrast agents uptake. DCE-CMR methods, which use
clinically available contrast agent, are widely used in can-
cer studies to assess tissue microvascularity and permea-
bility [74]. In atherosclerotic plaque, microvessels,
particularly those with high permeability, are thought to
be the primary route for inflammatory cell infiltrate.
These vessels also support existing macrophage metabo-
lism. Thus, using kinetic modeling [75], the DCE-CMR
parameters describing tissue microvascularity and perme-
ability are considered to be markers of inflammation
[76,77].
A parameter of kinetic modeling derived from the DCE-
CMR, fractional plasma volume (vp), is associated with a
histological assessment of actual microvessel area. A cor-
relation of 0.80 between vp measurements and the frac-
tional area of microvessels determined from histology
sections was found in 16 patients undergoing CEA, indi-
cating that vp was an effective marker of plaque microvas-
culature [78]. Another parameter of kinetic modeling, the
transfer constant (Ktrans) of the contrast agent, estimates
the permeability of microvessels. In 27 patients, with ana-
lyzable CMR images and corresponding histology
obtained from CEA, measurements of Ktrans were found to
correlate with macrophage (r = 0.75, p  < 0.001) and
microvessel (r = 0.71, p < 0.001) content [76]. A recent
study by Kerwin et al. has shown that Ktrans measurements
of the adventitial region of the carotid were significantly
correlated with serum markers of inflammation, such as
C-reactive protein levels (r = 0.57; p = 0.01) [77]. Figure 8
illustrates the steps necessary to calculate the vp and Ktrans,
which are represented by red (vp) and green (Ktrans) chan-
nel in vasa vasorum imaging (V-V image).
DCE-CMR comes with several further advantages. DCE-
CMR is easily integrated into existing CMR techniques for
vessel wall characterization; it is a short procedure lasting
minutes; it utilizes clinically available contrast agents that
are safe in people with normal renal function; and the
kinetic parameters can be measured with sub-millimeter
resolution.
Another contrast-enhanced CMR technique using Ultras-
mall Super-Paramagnetic Iron Oxide (USPIO) has been
shown to identify carotid inflammatory burden in human
The rupture prone atherosclerotic plaque has a thin fibrous  cap overlaying a large necrotic core Figure 3
The rupture prone atherosclerotic plaque has a thin 
fibrous cap overlaying a large necrotic core. This 
Movat's Pentachrome stain shows a carotid plaque with a 
large necrotic core (block arrow) containing hemorrhage 
(red staining). The fibrous cap shows a dramatic thinning 
near the shoulder of the core (arrow in the lumen). (Magnifi-
cation 10×)Journal of Cardiovascular Magnetic Resonance 2009, 11:53 http://www.jcmr-online.com/content/11/1/53
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studies  in vivo [79,80]. USPIO particles, which enter
atherosclerotic plaques with increased endothelial perme-
ability and accumulate in macrophages, are visualized as
a signal dropout or voids on CMR [81]. The accumulation
of USPIOs in macrophages is a slow process so that the
voids must be identified by comparing images obtained
before and, ideally, 36-48 hours after injection [82]. Areas
of focal signal loss on CMR images have been shown to
correspond to accumulation of macrophage infiltration
[83]. In a histological study, Trivedi et al. showed macro-
phages visualized by USPIO were present in 75% (27/36)
of the ruptured or rupture-prone plaques and 7% (1/14)
of the stable athermatous lesions [79].
Plaque Burden
In addition to the assessment of plaque composition, dis-
ruption, and biology, black-blood CMR also permits sim-
ple measurements of wall thickness, area, and volume.
These measurements are commonly grouped under the
name "plaque burden." Measurements of plaque burden
may be of particular importance in assessing the early for-
mation of atherosclerotic plaque. It has been conjectured
that the initiation of the atherosclerotic lesion begins
when low-density lipoprotein (LDL) cholesterol mole-
cules penetrate the arterial wall [37,84,85]. The lipids are
taken up by macrophages and become fatty streaks. Due
to the normal reactive response to injury (lipids), the arte-
rial wall thickens. Thus, early disease is most readily deter-
mined by wall thickness. Historically, the measurement of
arterial wall thickness has been performed by B mode
ultrasound (B-mode US) as the degree of intima-media
thickness (IMT) in the carotid artery. Several studies have
been shown that carotid vessel wall CMR can measure
arterial wall accurately [86] and reproducibly on multiple
scanner platforms [87], between scans and between read-
ers [88-90]. In addition, measurements of the wall thick-
ness by carotid vessel wall CMR have a high correlation
with the IMT by B-mode US. Underhill et al. found that a
high correlation between measurements of wall thickness
on B-mode US and CMR (r = 0.93, p < 0.001) [91]. Thus
carotid vessel wall CMR is well poised for use in studies of
early carotid atherosclerosis.
Clinical roles for carotid vessel wall CMR
Retrospective Risk
To establish the potential for carotid CMR to be used in
the assessment of stroke risk, numerous studies have ret-
rospectively investigated the relationship between prior
ischemic strokes or transient ischemic attacks and the
presence of disrupted plaque. In 23 unilateral sympto-
matic patients with > 50% stenosis on the symptomatic
side, Saam et al. showed an association between symp-
toms and ruptured plaques when compared to the asymp-
tomatic plaques (78% vs. 30%, p = 0.007) [92]. They also
found that symptomatic plaques were associated with a
higher occurrence of thrombus (61% vs. 26%, p = 0.039)
Atherosclerotic Carotid Artery Lipid-rich Necrotic Core Figure 4
Atherosclerotic Carotid Artery Lipid-rich Necrotic Core. Multi contrast black and bright blood sequences show a 
large lipid-rich necrotic core (small arrow) with an intact thick fibrous cap best seen in the post contrast T1 weighted (CE 
T1W) image (long arrow). Calcification is also visible at the base of the plaque (chevron). Asterisks are placed on the lumen.Journal of Cardiovascular Magnetic Resonance 2009, 11:53 http://www.jcmr-online.com/content/11/1/53
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[92]. Sadat et al. discovered the utility of multi-contrast
CMR while looking at carotid plaques of 60 patients,
fibrous cap rupture was observed in 50% of the acute
symptomatic patients, 35% of recently symptomatic
patients and no fibrous cap rupture was found in asymp-
tomatic patients [93]. Yuan et al. found that patients with
ruptured caps were 23 times more likely to have had a
recent TIA or stroke, compared with patients with thick
fibrous caps [94].
Additional studies have explored the relationship
between other features of the carotid plaque and prior
symptoms. Murphy et al. found that hemorrhage was
occurred significantly more common in the patients' ipsi-
lateral vessels compared with the contralateral, asympto-
matic side (60% vs. 36%, p < 0.001), and no hemorrhage
was found in a gender and age matched healthy control
group [95]. Howarth et al. also explored the degree of
CMR defined inflammation using USPIO particles,
between symptomatic and asymptomatic carotid plaques
[96]. They found that symptomatic patients had more
focal areas of signal drop than asymptomatic individuals
(75% vs. 32%, p < 0.01), thus suggesting that sympto-
matic plaques had large inflammatory infiltrates. Interest-
ingly, asymptomatic individuals more frequently showed
signal enhancement, which they attributed to low concen-
trations of USPIOs achieving positive contrast within
thicker fibrous caps. Furthermore, they reported that
some asymptomatic plaques also had focal areas of signal
drop by using USPIOs, suggesting an occult macrophage
burden [96].
Prospective Risk
A more compelling argument for carotid CMR risk assess-
ment comes from its ability to prospectively associate
CMR features of plaque with future development of symp-
toms. In a prospective study of 154 subjects with a mean
follow-up period of 38 months, Takaya et al. showed that
the presence of thin or disrupted fibrous cap, intraplaque
hemorrhage, larger lipid-rich necrotic core or thicker wall
was associated with an increased occurrence of subse-
quent neurological complications [97]. In a similar study,
Altaf et al. found that intraplaque hemorrhage was a good
predictor of ipsilateral stroke and TIA in 64 patients with
symptomatic mild to moderate (30%-69%) carotid steno-
sis over 2 years (hazard ratio = 9.8, p = 0.03) [98].
Plaque Natural History Studies
CMR has also played a role in understanding what aspects
of plaque morphology affect plaque progression and pop-
ulation differences in the disease. These factors may play
a role in improved, patient-specific treatment of the dis-
ease. In an ethnicity-based study, Saam et al. investigated
symptomatic carotid disease in Mainland Chinese
patients and a comparable group of Caucasian Americans
by using carotid vessel wall CMR [99]. They found signif-
MR bright-blood sequence Time of Flight (TOF), and black-blood sequences T1W, and MPRAGE show a hyperintense signal  (white block arrows) in the necrotic core Figure 5
MR bright-blood sequence Time of Flight (TOF), and black-blood sequences T1W, and MPRAGE show a 
hyperintense signal (white block arrows) in the necrotic core. Hematoxylin and Eosin (H&E) stained matching histol-
ogy shows a large necrotic core (broken lines) filled with hemorrhage. The hypointense signal (thin arrow) in the fibrous cap is 
shown by matching histology to be an area of calcification.
MP-RAGE T1W TOF
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icant differences between the Chinese and Americans for
the lipid-necrotic core (13.6 vs. 7.8 mm2, p = 0.002). Also
the wall area in the common carotid artery was larger in
the Chinese population (52.5 vs. 37.5 mm2, p = 0.007). In
a natural history study, Takaya et al. found that repeated
bleeding into the plaque may produce a stimulus for the
progression of atherosclerosis by increasing lipid core and
plaque volume and creating new destabilizing factors
[97]. Hemorrhage into the carotid atherosclerotic plaque
accelerated plaque progression in an 18-month period.
The change in wall volume (6.8% vs. -0.15%, p = 0.009)
and lipid-rich necrotic core volume (28.4% vs. -5.2%, p =
0.001) was significantly higher in the hemorrhage group
than in controls over the course of the study. Furthermore,
those with intraplaque hemorrhage at baseline were much
more likely to have new plaque hemorrhages at 18
months compared with controls (43% vs. 0%, p = 0.006).
Besides plaque composition change, in another natural
history study, Saam et al. identified factors that may alter
the rate of progression in plaque burden [100]. On aver-
age, the wall area increased by 2.2% per year (p = 0.001).
Findings from this study suggested that increased normal-
ized wall index (> 0.64, p = 0.001) and the use of statin
therapy (p = 0.01) were associated with reduced rates of
plaque burden progression amongst asymptomatic
patients (n = 68) with advanced carotid atherosclerosis
(stenosis ≥ 50%) over an 18-month period.
Pharmaceutical Trials
The ability of carotid vessel wall CMR to characterize
changes in plaque over time has had perhaps its greatest
impact in the evaluation of treatment effect in clinical tri-
als. Multiple, long-term, randomized studies have clearly
proven that statin therapy reduces clinical events [101-
103]. Several prospective CMR investigations have dem-
onstrated that statin therapy regresses carotid plaque bur-
den by using CMR [104,105]. In addition, statin therapy
has also been shown to specifically reduce the size of the
LRNC [106]. Recently, Zhao et al. reported carotid CMR
results from a randomized, double-blind clinical trial
directed at assessing the lipid-depletion hypothesis [107].
They found in subjects with a LRNC (n = 33), the LRNC
on average decreased by 12 mm3 (p = 0.007) in 1st year, by
13 mm3 (p = 0.004) in 2nd year, and by 0.7 mm3 (p = 0.3)
in 3rd year [107]. In addition, in the ORION trial (4522IL/
0044), Underhill et al. reported the similar effect of rosu-
vastatin on LRNC in the patients with moderate hyperc-
holesterolemia, regardless of high-dose (40 mg) or low-
dose (5 mg) randomization [106] over the course of 2
years of treatment (% LRNC: an overall reduction from
baseline of 41.4% ± 9.6%, p = 0.005). In a latter natural
history study, Underhill et al. found that statin therapy in
general was associated with a halting of plaque progres-
sion [108]. In this study, participants on statin therapy did
not demonstrate any significant change in plaque burden
after 18 months compared to the non-statin group that
had a significant increase in plaque size [108]. Interest-
ingly, this study also found that intraplaque hemorrhage
may offset the effects of statin therapy [108]. The study
suggested intraplaque hemorrhage mitigates the effects of
statins, an approach beyond lipid lowering therapy may
be necessary to counter the effects of intraplaque hemor-
rhage.
Calcification can be found in early atherosclerotic lesions Figure 6
Calcification can be found in early atherosclerotic lesions. Black and bright blood multicontrast images show the pres-
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More recently, there were several CMR based studies to
investigate the effects of statin therapy on macrophage
activity in carotid atherosclerotic plaques. Carotid Plaque
Composition (CPC) study is an ongoing study to investi-
gate the effect of intensive lipid therapy on DCE-CMR
defined inflammation [109]. After 1 year of treatment, a
statistically significant reduction was found in DCE-CMR
defined inflammation (Ktrans from 0.085 ± 0.037 to 0.067
± 0.028 min-1, p = 0.02). ATHEROMA was a study under-
taken to investigate the effects of low-dose (10 mg) and
high-dose (80 mg) atorvastatin on macrophage activity in
carotid atherosclerotic plaques using serial USPIO-
enhanced CMR [110]. A significant reduction from base-
line in USPIO-defined inflammation was observed in the
80-mg group at both 6 weeks (signal intensity change
[ΔSI] 0.13, p = 0.0003) and at 12 weeks (ΔSI 0.20, p <
0.0001). No difference was observed with the 10-mg
group. However, several drawbacks stand in the way of the
widely clinical application of USPIO-enhanced CMR. One
is that at least 2 CMR scans are required before and after
infusion of contrast medium. In addition, the calculation
of percentage reduction in signal loss needs to be more
reproducible since the signal reduction is dependent on
reproducibility of coil positioning and on image coregis-
tration before and after USPIO infusion.
Systemic Risk
A final area for carotid wall CMR that may be of clinical
relevance is the potential to use the carotid artery as a
marker of overall systemic disease. Individuals may go on
to develop atherosclerosis due to the process of aging. A
recent study by Keenan et al., imaged 100 healthy subjects
(10 per sex per decade), and found that even in normal
subjects the carotid wall volume increased with age [111].
The increase in wall volume correlates negatively with
wall distensibility giving rise to a combination of age and
pre clinical atherosclerosis related changes. These results
are important for further carotid MR studies of early
atherosclerosis.
The thickness of carotid arterial wall has correlated well
with increased risk factors for atherosclerosis, and the like-
lihood of future vascular events [112]. Mani et al. stated
that a greater wall thickness is prevalent among patients
with prior major cardiovascular or cerebrovascular events
(MACE) [113]. In their study (n = 195), patients with aged
50 years or older and with at least two risk factors for
atherosclerosis were recruited, they found that patients
with prior MACE had significantly higher MR wall thick-
ness in carotids and thoracic aorta compared to those
without prior MACE (Wall thickness carotids: 1.03 ± 0.03
vs. 0.93 ± 0.03, p = 0.001; wall thickness aorta: 1.63 ± 0.10
vs. 1.50 ± 0.04, p = 0.009, respectively). CMR provides a
new opportunity to investigate carotid disease as a sys-
temic marker of overall cardiovascular health.
Discussion
In summary, carotid vessel wall CMR appears poised for
use in clinical applications and is, in fact, having an indi-
rect clinical impact today through clinical trials involving
The Movat's Pentachrome stain of an atherosclerotic common carotid shows that a large lumen can mask complex inflammato- rylesions Figure 7
The Movat's Pentachrome stain of an atherosclerotic common carotid shows that a large lumen can mask 
complex inflammatorylesions. Inset A1 shows a well developed core surrounded by macrophages stained brown with the 
macrophage marker HAM 56 (arrows). Inset A2 is a high power view of the same lesion stained with the antibody to CD45RO 
and shows activated T cells on the lumen surface (short arrows). Inset B shows macrophages (brown) clustered on the lumen 
surface (short arrow) and throughout the neointima (short arrow) indicating plaque activity and progression. (Magnification 
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carotid CMR. Numerous studies support the hypothesis
that features of the carotid vessel wall identified with CMR
can segregate individuals with similar degrees of stenosis
into higher and lower risk categories. Thus, carotid vessel
wall CMR is a promising candidate to be an additional
diagnostic tool for management of patients with carotid
atherosclerosis. The achievements of carotid vessel wall
CMR to date strongly indicate the need for a large multi-
center trial of its merits for patient management.
Additionally, CMR technology applicable to carotid vessel
wall imaging is evolving rapidly. Within the next decade,
considerable new techniques are expected to further refine
our capabilities in charactering carotid atherosclerosis.
Most notably, molecular imaging techniques are being
developments for highly specific enhancement of compo-
nents such as fibrin [114], angiogenic integrins [115],
macrophage receptors [116], and lipid-rich areas [117].
Ultimate use of these technologies in human is, however,
uncertain. In this review, we addressed only technologies
that would be suitable for clinical use immediately if indi-
cated.
Also, the vessel wall imaging capabilities of CMR are not
limited to the carotid arteries. Imaging methods devel-
oped for carotid artery may be translated to other beds,
although each one has to tailor to the local environment.
Like carotid arteries, femoral arteries are relatively accessi-
ble to surface coils and benefit most from improvements
in field-strength and surface coil design [118]. In contrast,
owing to their size and complex anatomy, coronary and
aortic images are impeded by various factors [119,120].
For example, motion compensation needs to be consid-
ered in coronary and aortic arteries. Image quality may be
improved by using cardiac and respiratory gating. In addi-
tion, blood flow velocities and directions in different arte-
rial beds should be considered as they determine blood
suppression efficiency in most black-blood techniques.
In conclusion, CMR of the early and advanced atheroscle-
rotic plaque has shown promise in providing understand-
ing of the biology of the disease and a potential to provide
clinical risk assessments for individual carotid atheroscle-
rotic plaques. Multi-contrast CMR is currently in use in
clinical trials to determine the effectiveness of new drugs
and therapies. The capacity to non-invasively monitor the
disease may lead to novel therapeutic targets that are asso-
ciated with rapid progression or a muted response to con-
ventional treatments. With the continual development of
CMR techniques, vessel wall CMR is likely to be widely
used for atherosclerosis management clinically in the near
future.
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Contrast Enhanced MRI (DCE-MRI) with Kinetic Remodel Figure 8
Contrast Enhanced MRI (DCE-MRI) with Kinetic Remodel. V-V image generated by the dynamic contrast enhanced 
MRI (DCE-MRI) with kinetic remodel. Illustration of the steps in creating a vasa vasorum image: boundaries drawn on a con-
ventional contrast define a region of interest for processing. Within this region, DCE-MRI images are run through the KFRS 
algorithm, and then a blood curve (AIF) is automatically extracted and used for kinetic modeling. Finally, the boundaries are 
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